Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. is a biotechnology company focused on human genetics for the treatment of neurological diseases. Its pipeline includes VY1706, a tau-silencing gene therapy, and VY7523, an anti-tau antibody program, both directed at Alzheimer's disease, as well as a research program in Huntington's disease and selective small molecules for amyotrophic lateral sclerosis and frontotemporal dementia with TDP-43 pathology. The company also offers TRACER, an adeno-associated virus (AAV) capsid discovery platform, and ALPL-VYGR-NeuroShuttle, aimed at an undisclosed neurological disease.

Third-party pipeline data associates the company with 24 drugs and 6 clinical trials, with therapeutic activity concentrated in nervous system diseases (21 programs) and endocrinology/metabolic disease (10), and drug modalities led by AAV-based gene therapy (13), miRNA (5), gene therapy (3), siRNA (3) and antibodies (1). Most frequently developed targets include TAU, FXN, SOD1, SMN1 and GBA1. Named clinical assets include VY-AADC (Phase 2, originated at the University of California, DDC gene transference), VY7523 (Phase 1/2, TAU inhibitor for Alzheimer's disease) and the preclinical VCAP-101 for brain metastases.

Voyager was incorporated in 2013 in Delaware and is headquartered at 75 Hayden Avenue, Lexington, Massachusetts. It trades on NASDAQ under the ticker VYGR (CIK 0001640266; SIC code 2836) and reported 141 employees as of an August 2026 profile update.

Founding story

Voyager Therapeutics was incorporated in 2013 (one source lists 2014 as the founding year). Krystof Bankiewicz, M.D., Ph.D. and Mark A. Kay, M.D., Ph.D. are listed as founders.

Business model

Voyager develops proprietary therapeutic candidates for neurological diseases and also licenses/partners its technology: it has collaboration and license agreements with Alexion, AstraZeneca Ireland Limited, Novartis Pharma AG and Transition Bio, Inc. covering various central nervous system diseases, and its TRACER AAV capsid discovery platform underpins both internal programs and partnered work.

Sources indicate revenue-generating potential through collaboration and license agreements with pharmaceutical partners; no revenue figures are disclosed in the available sources.

Traction

Publicly documented traction includes an IPO on NASDAQ in November 2015, 24 associated drugs and 6 associated clinical trials in third-party pipeline data, a Phase 2-stage asset (VY-AADC), an ongoing Phase 1/2 trial of VY7523 in early Alzheimer's disease initiated in March 2025, and multiple pharmaceutical collaboration and license agreements.

Latest developments

In March 2025 Voyager began NCT06874621, a randomized, placebo-controlled, double-blind Phase 1/2 study of multiple ascending intravenous doses of VY7523 in participants with early Alzheimer's disease, following first testing in healthy volunteers. As of an August 2026 profile update the company had 141 employees and its shares traded around $3.35 on NASDAQ. Company scientists published on rAAV analytics methods, including a July 2025 Human Gene Therapy article describing a ddPCR-based method for quantitating rAAV cellular uptake.